Table 4. . Final peripheral neuropathy sensitivity model including clinical and genetic predictors.

Predictor	PN sensitivity model with FZD3 rs7833751			PN sensitivity model with FZD3 rs7833751 and EPHA5 rs7349683			Ref.
	Beta†	95% CI	p-value	Beta†	95% CI	p-value
Each additional FZD3 rs7833751 variant allele a patient carried	-0.41	-0.66 to -0.17	0.0011	-0.47	-0.72 to -0.23	<0.001
Baseline CIPN8	0.19	0.12–0.25	<0.001	0.18	0.12–0.24	<0.0001
Cumulative dose	-0.13	-0.55–0.29	0.55	-0.14	-0.56–0.28	0.52
Relative dose intensity	-1.53	-3.01 to -0.04	0.04	-1.44	-2.91–0.03	0.06
Tc>0.05	-0.23	-0.45 to -0.02	0.03	-0.31	-0.53 to -0.10	<0.01
Cumulative dose Tc>0.05 interaction†	0.14	0.04–0.25	<0.01	0.14	0.04–0.25	<0.01
Each additional EPHA5 rs7349683 variant allele a patient carried	–	–	–	0.47	0.19–0.75	<0.01	[31]

^†Positive beta-coefficient indicates higher PN sensitivity, negative indicates lower PN sensitivity.

PN: Peripheral neuropathy.